Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Building Ethical Enterprises: How Vibhavangal Anukulakara Pvt. Ltd. Is Redefining Growth with Integrity and Innovation Press Release
  • PR QUEEN: Dr. Piyali Roy Crowns Dr. Nidhi Ojha as Mrs. Universe India–USA 2026 to Represent India on the Global Stage Lifestyle
  • Lagnam Spintex Commences Commercial Production Ahead of Schedule Business
  • Shivani Rahangdale Sawant Wins 2nd Runner Up at Mrs. India Universal Woman 2025, Inspiring Women Nationwide Lifestyle
  • Indian study reveals a blend of anti-oxidants with micronutrients showed statistically significant improvement in all male-fertility parameters Press Release
  • Chief Minister Bhupendra Patel Reviews Progress Of Dholera SIR, Visits GAP Group’s Integrated Township Site National
  • Special Hanuman Chalisa organised in Surat for hero Capt. Smit Machchhar Lifestyle
  • Starting his entrepreneurial journey in college, Krishna is now an owner of multiple companies in India and Singapore Business

Killer Cough Syrup Coldrif Ban Sparks Drug Reform

Posted on October 11, 2025 By

New Delhi [India], October 11: After 20 child deaths in Madhya Pradesh, Delhi banned the killer cough syrup Coldrif. But this tragedy is now driving India’s biggest clean-up of its drug manufacturing ecosystem in years.

A Tragedy That Triggered a Reckoning – Killer Cough Syrup

Sometimes it takes a crisis to wake up a system. The deaths linked to Coldrif cough syrup, manufactured by Sreesan Pharmaceuticals in Tamil Nadu, have done just that.

Investigators found 48.6% diethylene glycol, a toxic industrial solvent, in samples, hundreds of times above the safety limit. The same chemical has caused tragedies abroad. But this time, India didn’t shrug and move on.

Within days, Delhi, Kerala, Punjab, Tamil Nadu, and Uttar Pradesh banned the syrup. The Union Health Ministry launched a national crackdown on substandard formulations. And for the first time in a long time, the drug regulators and state governments are acting in sync.

Swift Action, Not Silence

The Delhi Drugs Control Department issued a public ban on October 10, declaring Coldrif “Not of Standard Quality” and “injurious to health.”
The order directed every pharmacy, distributor, and citizen to stop sale and use immediately.

Instead of the usual bureaucratic limbo, this was a clear, fast response, backed by states across India. Delhi led, others followed. That’s what good governance looks like.

Behind the Numbers, Human Stories

Every reform story begins with pain. Parents in Parasia, Madhya Pradesh, still carry photos of the children they lost. They went to trusted local doctors, seeking a simple cure for cough and fever. What they got instead was tragedy.

But their grief is now driving change. It has pushed regulators, doctors, and manufacturers into one urgent question: how did toxic solvents end up in a children’s syrup, and how do we make sure it never happens again?

India’s Drug System Under the Microscope

The answer lies in India’s layered but fragmented regulatory system.
The Central Drugs Standard Control Organisation (CDSCO) approves new drugs and oversees imports, while state regulators handle manufacturing licenses. That’s a lot of moving parts, and sometimes, too many blind spots.

The good news? Those gaps are finally being filled.

Following the Coldrif incident, CDSCO chief Dr. Rajeev Singh Raghuvanshi issued a directive on October 7 to all States and Union Territories: test all raw materials, excipients, and finished drugs thoroughly under the Drugs Rules, 1945.

It’s not just talk. States are now conducting joint audits, modernising testing labs, and creating a national database of manufacturers. The goal: traceability from factory to pharmacy, every batch logged, every bottle accountable.

Accountability Without Delay

In Tamil Nadu, the source state, action was swift and decisive. The government suspended two senior drug inspectors and cancelled Sreesan Pharma’s license. The factory, located near Kancheepuram, was sealed after inspections found over 300 quality violations.

The company’s proprietor, G. Ranganathan, was arrested on October 9. Investigations revealed that the manufacturer had used non-pharmacopoeial grade solvents, likely contaminated with diethylene glycol.

This time, the message from regulators was clear: Cutting corners is no longer cheap, it’s criminal.

A Reform Moment for Indian Pharma

India’s pharmaceutical industry is one of the world’s largest, supplying affordable medicine to over 200 countries. But incidents like Coldrif remind us that scale must be matched with safety.

The Central and State governments are now using this as a pivot point.

  • Nationwide audits of cough syrup makers have begun.
  • The World Health Organization has been formally notified of the recalls.
  • New guidelines for continuous quality monitoring are being implemented.

Industry leaders are also stepping up. Several pharma associations have begun internal compliance checks and training drives for small and medium manufacturers, a move that could reshape India’s pharmaceutical credibility globally.

From Crisis to Course Correction

To be fair, India has faced diethylene glycol scares before, in 1986, and again in 2022 when exported syrups caused child deaths abroad. Each time, the system promised reform.
This time, it’s delivering.

The new joint regulatory audit model, backed by the Health Ministry and CDSCO, ensures every state shares accountability. The Ministry is also pushing for AI-based tracking of manufacturing and distribution chains, something that can identify red flags before they hit pharmacy shelves.

That’s not damage control, that’s evolution.

Ground-Level Vigilance

In Madhya Pradesh, over 4,000 frontline workers, ASHAs, nurses, and Anganwadi staff, have been conducting door-to-door checks to seize leftover bottles of Coldrif. As of October 10, more than 540 bottles have been recovered and destroyed safely.

This people-first approach shows the system learning from past mistakes. It’s no longer just about punishment, it’s about prevention.

A Global Reputation at Stake, and Strengthened

India’s “pharmacy of the world” tag comes with immense responsibility. When something goes wrong here, it echoes globally. But the Coldrif case could end up reinforcing India’s seriousness about safety rather than undermining it.

By moving fast, auditing openly, and owning the problem, India is showing that transparency is its strongest antidote.

As one senior CDSCO official put it, “We can’t control every mistake. But we can control how fast we fix it.”

Stronger, Cleaner, Safer

The Coldrif ban is not just about a single syrup; it’s about the system’s reset.

From Delhi’s ban to Tamil Nadu’s crackdown, from DCGI’s directives to on-ground vigilance, India’s drug oversight is entering a new era of accountability. The tragedy that began in Parasia may well become the turning point that made Indian medicine safer for everyone.

PNN News

National Tags:national

Post navigation

Previous Post: Focus Bags INR 1.88 Cr Gandhinagar LED Lighting Project
Next Post: International Solar Alliance to host the Eighth Session of the ISA Assembly from 27-30 October in India

Related Posts

  • New UPI transaction limit hike: Big relief for high-value payments from today National
  • Role of Grassroots in National Elections: Case Study from Village India National
  • Hair For Hope: Kapils Salon & Academy, CanKids KidsCan NGO & Deutsche Bank Team Up for Childhood Cancer Awareness National
  • World Tourism Day 2025 India – Bold Step to Sustainable Growth National
  • Samridhhi Mandawat – the Youngest Female Author to have donated all the Royalties for Women Upliftment English
  • Central Cottage Industries Corporation brings “Best of Art and Craft Exhibitions” from Telangana, Know all the details here National

Recent Posts

  • India Financial Planning Summit 2026 Brings Together Regulators, Industry Leaders and CFP® Professionals to Strengthen India’s Financial Planning Ecosystem
  • One Requirement, Multiple Teams: How Officebing Plans Workplaces Around Different Functions
  • Indogulf Cropsciences Delivers Strong Q2 FY27 Performance: EBITDA Rises 27%, PAT Grows 24%; EBITDA Margin Expands 300 bps to 16%
  • IIM Calcutta launches inaugural AI-Powered Product Management programme
  • Delta Autocorp Reports 27% PAT Growth to Rs 4.33 Crore in H1 FY27

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Sterling Holiday Resorts Announces a Brand-New Upscale Resort in Sariska Business
  • Svdaa: we are excited to launch our new Beauty care Brand Svdaa Business
  • Vipul Joshi & Associates expands immigration advisory services to Ahmedabad Business
  • President Murmu’s Visit to Pune: Rakesh Mittal Highlights Educational and Cultural Growth National
  • YAAP Digital Announces Leadership Transition; Appoints Raj Nayak as Chairman & Managing Director Business
  • Sravani Hospitals, Madhapur, launched its website and honored 53 doctors on National Doctors’ Day Business
  • Creative first launches ‘Your IP Your Future’ campaign to protect India’s creative industries Business
  • Homoeopathic Treatments for Aplastic Anemia: International homeopathic Conference London United Kingdom Health

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme